Your browser doesn't support javascript.
Vulnerability Predictors of Post-Vaccine SARS-CoV-2 Infection and Disease-Empirical Evidence from a Large Population-Based Italian Platform.
Corrao, Giovanni; Franchi, Matteo; Cereda, Danilo; Bortolan, Francesco; Leoni, Olivia; Borriello, Catia Rosanna; Della Valle, Petra Giulia; Tirani, Marcello; Pavesi, Giovanni; Barone, Antonio; Ercolanoni, Michele; Jara, Jose; Galli, Massimo; Bertolaso, Guido.
  • Corrao G; National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, 20126 Milan, Italy.
  • Franchi M; Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 20126 Milan, Italy.
  • Cereda D; National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, 20126 Milan, Italy.
  • Bortolan F; Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 20126 Milan, Italy.
  • Leoni O; Directorate General for Health, Lombardy Region, 20124 Milan, Italy.
  • Borriello CR; Directorate General for Health, Lombardy Region, 20124 Milan, Italy.
  • Della Valle PG; Directorate General for Health, Lombardy Region, 20124 Milan, Italy.
  • Tirani M; Directorate General for Health, Lombardy Region, 20124 Milan, Italy.
  • Pavesi G; Directorate General for Health, Lombardy Region, 20124 Milan, Italy.
  • Barone A; Directorate General for Health, Lombardy Region, 20124 Milan, Italy.
  • Ercolanoni M; Directorate General for Health, Lombardy Region, 20124 Milan, Italy.
  • Jara J; Azienda Regionale per l'Innovazione e gli Acquisti (ARIA) S.p.A., 20124 Milan, Italy.
  • Galli M; Azienda Regionale per l'Innovazione e gli Acquisti (ARIA) S.p.A., 20124 Milan, Italy.
  • Bertolaso G; Azienda Regionale per l'Innovazione e gli Acquisti (ARIA) S.p.A., 20124 Milan, Italy.
Vaccines (Basel) ; 10(6)2022 May 26.
Article in English | MEDLINE | ID: covidwho-1869853
ABSTRACT
We aimed to identify individual features associated with increased risk of post-vaccine SARS-CoV-2 infection and severe COVID-19 illness. We performed a nested case-control study based on 5,350,295 citizens from Lombardy, Italy, aged ≥ 12 years who received a complete anti-COVID-19 vaccination from 17 January 2021 to 31 July 2021, and followed from 14 days after vaccine completion to 11 November 2021. Overall, 17,996 infections and 3023 severe illness cases occurred. For each case, controls were 11 (infection cases) or 110 (severe illness cases) matched for municipality of residence and date of vaccination completion. The association between selected predictors (sex, age, previous occurrence of SARS-CoV-2 infection, type of vaccine received, number of previous contacts with the Regional Health Service (RHS), and the presence of 59 diseases) and outcomes was assessed by using multivariable conditional logistic regression models. Sex, age, previous SARS-CoV-2 infection, type of vaccine and number of contacts with the RHS were associated with the risk of infection and severe illness. Moreover, higher odds of infection and severe illness were significantly associated with 14 and 34 diseases, respectively, among those investigated. These results can be helpful to clinicians and policy makers for prioritizing interventions.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10060845

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10060845